Content
Content
Team
Team
Companies
Companies
About
About
Products
Products
Signal
Brieflink
NFX Masterclass
Get our weekly newsletter that 322K+ startup teams read
Subscribe
Omri Amirav-Drory, Ph.D.
45
Focus Areas
All Focus Areas
Cybersecurity
· 4
Bio
· 37
Gaming
· 6
AI
· 52
PropTech
· 5
Space
· 6
Fintech
· 5
Marketplaces
· 26
Crypto
· 18
Silicon Valley
· 6
Israel
· 11
Europe
· 4
LatAm
· 4
By Author
Anna Piñol
Anastasia Budinskaya
Daniel Museles
Valerie Osband Mahoney
Morgan Beller
Omri Amirav-Drory, Ph.D.
Pete Flint
Gigi Levy-Weiss
James Currier
Topics
Network Effects
· 35
Fundraising
· 29
Growth
· 123
Leadership
· 58
Investment Memos
· 66
Psychology
· 58
Announcements
· 29
By Type
All NFX Content
· 442
Videos
· 38
Podcasts
· 90
Essays
· 175
Omri Amirav-Drory, Ph.D. · 45
Featured
The Next Industrial Revolution: Computational Biology & Bioplatforms
Featured
NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Featured
Why C2i is the World’s First Platform for Cancer Intelligence
The Case for Venture Capital in the Age of Superintelligence
The Last Problem For AI to Solve is Health
“Find a Way to Break Reality”: How Centivax Brought a Universal Flu Vaccine to Clinic
In Vitro, In Vivo, In China: How Early-Stage Companies Are Reaching the Clinic Faster Than Ever
Promoting Anastasia Budinskaya to Principal
The Founder’s Guide to JPM
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models
The AI Utopia Doesn’t Exist Without Bio
The Seasons of Fundraising
Women’s Health 2.0: Beyond Fertility
Longevity Can Save America
Why Don’t Billionaires Invest In Longevity?
Longevity’s First Blockbuster
The “Intangible” Game: How VCs See You
Why Great Bioplatforms Will Always Win
How to Start Your Own VC Fund
The Race to 160
Why NFX Invested in TwoStep Therapeutics: One Elegant Platform Targeting 90% of Cancers
How VCs Become Assholes
The Business Case for Longevity
Featured
The Next Industrial Revolution: Computational Biology & Bioplatforms
Featured
NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Featured
Why C2i is the World’s First Platform for Cancer Intelligence
The Case for Venture Capital in the Age of Superintelligence
The Last Problem For AI to Solve is Health
“Find a Way to Break Reality”: How Centivax Brought a Universal Flu Vaccine to Clinic
In Vitro, In Vivo, In China: How Early-Stage Companies Are Reaching the Clinic Faster Than Ever
Promoting Anastasia Budinskaya to Principal
The Founder’s Guide to JPM
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models
The AI Utopia Doesn’t Exist Without Bio
The Seasons of Fundraising
Women’s Health 2.0: Beyond Fertility
Longevity Can Save America
Why Don’t Billionaires Invest In Longevity?
Longevity’s First Blockbuster
The “Intangible” Game: How VCs See You
Why Great Bioplatforms Will Always Win
How to Start Your Own VC Fund
The Race to 160
Why NFX Invested in TwoStep Therapeutics: One Elegant Platform Targeting 90% of Cancers
How VCs Become Assholes
The Business Case for Longevity
Load More Content
Subscribe for more startup insights
Get our weekly newsletter that 322K+ startup teams read
Subscribe